Related Experiment Video
Updated: Jun 2, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?
Tahmeed Contractor1, Atul Khasnis
1Department of Medicine, Michigan State University, B301 Clinical Center, East Lansing, MI 48824, USA.
Insights
Atrial Fibrillation (AF) stroke risk is high, especially in the elderly. Percutaneous left atrial appendage (LAA) occlusion offers a new stroke prevention method, targeting clot formation in the LAA.
Area of Science:
- Cardiology
- Medical Devices
- Stroke Prevention
Background:
- Atrial Fibrillation (AF) is a prevalent arrhythmia, particularly in older adults, significantly increasing stroke risk.
- Warfarin reduces AF-related stroke but has limitations due to bleeding concerns and compliance issues.
- The left atrial appendage (LAA) is a primary source of thrombus formation in nonvalvular AF.
Purpose of the Study:
- To review the emerging field of percutaneous LAA occlusion for stroke prevention in AF patients.
- To discuss the challenges with current anticoagulation therapies for AF.
- To explore the LAA as a novel therapeutic target.
Main Methods:
- Literature review focusing on stroke risk in AF, limitations of warfarin, and the role of the LAA.
- Analysis of the feasibility and efficacy of various percutaneous LAA occlusion devices.
- Discussion of current evidence and future directions in LAA occlusion technology.
Main Results:
- Percutaneous LAA occlusion is an evolving therapeutic strategy for stroke prevention in AF.
- Several devices have been developed to occlude the LAA, aiming to reduce thrombogenesis.
- The efficacy and safety profiles of these devices are under active investigation.
Conclusions:
- LAA occlusion presents a promising alternative to long-term anticoagulation for selected high-risk AF patients.
- Further research is needed to establish optimal device selection and long-term outcomes.
- Minimally invasive LAA occlusion aims to mitigate stroke burden in AF.
Abstract:
Atrial Fibrillation (AF) is a common arrhythmia with an incidence that is as high as 10% in the elderly population. Given the large proportion of strokes caused by AF as well as the associated morbidity and mortality, reducing stroke burden is the most important part of AF management. While warfarin significantly reduces the risk of AF-related stroke, perceived bleeding risks and compliance limit its widespread use in the high-risk AF population. The left atrial appendage is believed to be the "culprit" for thrombogenesis in nonvalvular AF and is a new therapeutic target for stroke prevention. The purpose of this review is to explore the evolving field of percutaneous LAA occlusion. After briefly highlighting the risk of stroke with AF, problems with warfarin, and the role of the LAA in clot formation, this article discusses the feasibility and efficacy of various devices which have been developed for percutaneous LAA occlusion.
